Stay updated on Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial page.

Latest updates to the Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial page
- CheckyesterdayChange DetectedThe page’s footer version/release label was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” indicating a site software update without changing the clinical trial information displayed.SummaryDifference0.0%

- Check8 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check37 days agoChange DetectedThe site revision tag was updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check44 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check73 days agoChange DetectedPrimary peritoneal carcinoma was added to the listed conditions and a new Resources entry for the Genetic and Rare Diseases Information Center was included; the revision notes indicate a version update from v3.4.1 to v3.4.2.SummaryDifference0.2%

- Check80 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1. This appears to be a minor backend/content management update with no changes to study content.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial page.